Dai ichi Life Insurance Company Ltd Lowers Stake in Insulet Co. (NASDAQ:PODD)

Dai ichi Life Insurance Company Ltd reduced its position in Insulet Co. (NASDAQ:PODD) by 71.9% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 3,988 shares of the medical instruments supplier’s stock after selling 10,200 shares during the period. Dai ichi Life Insurance Company Ltd’s holdings in Insulet were worth $928,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Blue Trust Inc. increased its holdings in shares of Insulet by 84.1% during the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 58 shares in the last quarter. International Assets Investment Management LLC acquired a new position in shares of Insulet during the second quarter valued at about $32,000. Venturi Wealth Management LLC increased its holdings in shares of Insulet by 633.3% during the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 133 shares in the last quarter. UMB Bank n.a. increased its holdings in shares of Insulet by 81.0% during the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after acquiring an additional 81 shares in the last quarter. Finally, CVA Family Office LLC increased its holdings in shares of Insulet by 138.1% during the second quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after acquiring an additional 145 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on PODD shares. Barclays upped their price objective on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Citigroup upped their target price on Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a research report on Tuesday, October 1st. Raymond James upped their target price on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research report on Monday, October 14th. Morgan Stanley upped their target price on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. Finally, BTIG Research upped their target price on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Three equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $253.27.

Insulet Trading Up 0.2 %

Insulet stock opened at $266.92 on Friday. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $279.40. The stock’s 50 day simple moving average is $243.21 and its two-hundred day simple moving average is $212.74. The firm has a market cap of $18.72 billion, a PE ratio of 45.71, a P/E/G ratio of 4.08 and a beta of 1.22.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.